Gilead Sciences has said it will soon start a clinical trial in Europe of its twice-yearly HIV injection Sunlenca for pre-exposure prophylaxis (PrEP), a potential successo
The European Commission has become the first regulator worldwide to approved a therapy from Gilead Sciences for people with multidrug-resistant (MDR) HIV infection that only needs to be tak
Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in Februa
The FDA has given ViiV healthcare and Johnson & Johnson a boost in the market for long-acting injectable HIV drugs, approving a new regimen for their Cabenuva product that does away wit
Gilead Sciences has filed for FDA approval of a long-acting therapy for resistant HIV infections that only needs to be administered once every six months.
Scientists have developed a new test for a biomarker in brain tissue that could detect people who will go on to develop motor neuron disease (MND) before they show symptom